Injured by side effects of Avandia (rosiglitazone)?
In November of 2007, the FDA announced that the manufacturer of Avandia (rosiglitazone) agreed to place a new Black Box Warning on the drug’s label concerning a potential increased risk for heart attacks.
GlaxoSmithKline’ s Avandia (rosiglitazone) was developed to help control blood sugar in adults with Type 2 Diabetes.
In an article appearing in the June 14, 2007 edition, the New England Journal of Medicine details a recent analysis of clinical trials suggesting that the use of Avandia significantly increases the risk of heart attacks and cardiovascular death. The study was conducted by doctors at the renowned Cleveland Clinic and was published on May 21, 2007.
The trials compared patients taking Avandia with those not using the drug. The results indicate that Avandia users had an increase of cardiac-related death by 64 percent and a 43 percent increase in heart attacks.
In a Safety Alert issued May 21, 2007, the U.S. Food and Drug Administration said patients taking Avandia, especially those with heart disease or at high risk of heart attack, should talk to their doctor about the risks.
Since the drug was approved, the FDA has monitored several heart-related adverse events associated with Avandia, such as fluid retention, edema and congestive heart failure. The FDA repeatedly has updated the product's labeling to reflect these concerns.
Free Case Evaluation — We offer proven representation in defective drug and products liability cases, serving clients in the Kansas City metro area and throughout Missouri and Kansas. Call 816.421.6868.
If you have experienced a heart attack or a love one has died of heart related (cardiovascular) disease after using the diabetes medication Avandia, you should contact our Kansas City law office at 816.421.6868 or by e-mail. We provide a free, one-on-one consultation with an experienced attorney.
